Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 12/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797706 | 0.80 | NR1H2 (0.44) | NR1H2TMEM97KCNH2SIGMAR1PDK2 | |
| SCHEMBL14067293 | 0.74 | PDK2 (0.43) | NR1H2PDK2HSD17B3NAMPTHDAC8 | |
| SCHEMBL26640019 | 0.73 | NR1H2 (0.43) | NR1H2PDK2HSD17B3NAMPTHDAC8 | |
| SCHEMBL30648706 | 0.73 | NR1H2 (0.43) | NR1H2PDK2HSD17B3NAMPTHDAC8 | |
| SCHEMBL25856118 | 0.73 | NR1H2 (0.49) | NR1H2TMEM97KCNH2SIGMAR1PDK2 | |
| SCHEMBL13405609 | 0.71 | NR1H2 (0.47) | NR1H2PDK2HSD17B3HDAC8 | |
| SCHEMBL17797585 | 0.71 | NR1H2 (0.54) | NR1H2PDK2HSD17B3 | |
| SCHEMBL188773 | 0.70 | KDM4E (0.43) | NR1H2PDK2HSD17B3NAMPT | |
| SCHEMBL30885125 | 0.69 | ATAD2 (0.47) | NR1H2PDK2HSD17B3NAMPTHDAC8 | |
| SCHEMBL27981478 | 0.69 | HSD17B3 (0.43) | NR1H2PDK2HSD17B3NAMPTHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091345-B2 | Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1560831-A1 | NOVEL AMINO-SUBSTITUTED DIHYDROPYRIMIDO [4,5-D] PYRIMIDIN ONE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041823-A1 | NOVEL AMINO-SUBSTITUTED DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087600-A1 | Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives | HOFFMANN-LA ROCHE INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087600-A1 | Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives | SRC, ABL1, LCK | NR1H2 3412/4885TMEM97 2705/4885KCNH2 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.